Cremers, G.J.

diarrhea patient irinotecan neomycin cancer study grade irinotecan-induced delayed-type -38 sn -38 treatment irinotecan-induced delayed-type diarrhea effect pharmacokinetic hospital oncol ugt 1a allele toxicity delayed-type diarrhea irinotecan-induced diarrhea verweij j colorectal october incidence mathijssen placebo colorectal cancer cancer patients β- glucuronidase activity prophylactic randomized downloaded erasmus university allele oncologist analysis center severity oncologist ® netherland irinotecan-induced delayedtype diarrhea trial grade 2–3 diarrhea verweij metastatic colorectal cancer grade 3 diarrhea pharmacogenetic group neutropenia genotype nci-ctc rotterdam jonge mj pilot study center rotterdam neutrophil count metabolite jong fa blood placebo-controlled study floris kehrer prophylaxi result sn -38 exposure 10.1634/ theoncologist .11-8-944 oncology toxicity criteria 3 days ugt 1a exposure phase variant parameter alphamed press regimen infusion placebo-controlled bruijn p table